SILEXION THERAPEUTICS CORP (SLXN)

Healthcare · Biological Products, (No Diagnostic Substances) · Price $0.37
Updated: Sep 1, 2026
Below Average Equity Returns — Healthcare
ROE of -563.11% — below the 10% floor Zyberno applies to Healthcare businesses.
ROE
-563.11%
Return on Equity
ROIC
-525.30%
Return on Invested Capital
ROA
-201.73%
Return on Assets
Debt/Equity
9.66x
Leverage Ratio
Book Value/Share
$0.06
Equity Per Share

🧮 SLXN ROE Calculation

ROE = Net Income / Shareholders' Equity
Net Income (TTM) $-14.0M
Shareholders' Equity $44.0K
Total Debt $425.0K
Debt-to-Equity Ratio 9.66x
ROE (Return on Equity) -563.11%

Understanding ROE

Return on Equity (ROE) measures how efficiently a company generates profits from shareholders' equity. For SLXN, the current ROE is -563.11%.

Why ROE Matters

Warren Buffett has called ROE one of his favorite metrics because it shows how well management uses shareholders' capital to generate returns. A company that consistently earns 15%+ ROE is typically a well-run business that creates value for shareholders.

High Leverage Warning

SLXN's debt-to-equity ratio of 9.66x is elevated. High ROE combined with high debt can be a red flag — the company may be using financial leverage to boost returns, which increases risk. Compare to ROIC for a more complete picture.

ROE Benchmarks

Excellent: >20%

Exceptional returns on equity. Often indicates strong competitive advantages. Common in capital-light businesses.

Good: 15-20%

Above-average ROE. Buffett often looks for companies in this range or higher.

Average: 10-15%

Typical for most companies. Returns are reasonable but not exceptional.

Below Average: <10%

May indicate poor capital allocation or challenging business conditions.

The DuPont Analysis

ROE can be decomposed into three components using DuPont analysis:

ROE = Net Margin × Asset Turnover × Equity Multiplier

This breakdown reveals whether high ROE comes from high profitability (good), efficient asset use (good), or high leverage (potentially risky).

ROE vs ROIC: Which is Better?

ROIC: -525.30% →

ROIC measures returns on ALL capital. It's more comprehensive and less affected by leverage. Often considered the better quality metric.

ROE: -563.11%

ROE only measures returns on equity. Can be inflated by high debt. If ROE >> ROIC, the company uses significant leverage.

Owner Earnings: $-12.4M →

Shows actual cash available to owners. Use alongside ROE and ROIC for complete analysis.

Net Income: $-14.0M →

The numerator in ROE. Understanding net income trends helps explain ROE changes over time.

What to Look For

📊 Full SLXN Stock Report

Intrinsic value, margin of safety, DCF valuation, and 250+ metrics.

🏆 SLXN ROIC

Compare ROE to ROIC — the more comprehensive measure of capital efficiency.

💹 SLXN P/E Ratio

Analyze valuation relative to earnings and understand market pricing.

👤 SLXN Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 SLXN Net Income

See the earnings that drive ROE calculations.

💵 SLXN Free Cash Flow

Actual cash generation after capital expenditures.

View Full SLXN Report Find More Quality Stocks
📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
🛡️
Margin of Safety
Valuation Gap
🎯
Expected Return
Projected Annual
Click any metric for full methodology and detailed analysis

Summary: SLXN Return on Equity

SILEXION THERAPEUTICS CORP (SLXN) has a ROE of -563.11% — below the 10% floor Zyberno applies to healthcare companies where IP and regulatory advantages drive equity returns, indicating weak returns on shareholders' capital. Note: with a debt-to-equity of 9.66x, leverage is amplifying these returns — compare with ROIC (-525.30%) for a leverage-neutral view. For complete financial analysis, view the full SLXN stock report on Zyberno.

Frequently Asked Questions

What is SLXN's current ROE?

SILEXION THERAPEUTICS CORP's Return on Equity (ROE) is -563.11%, measured against the 20% excellent threshold Zyberno applies to Healthcare businesses. ROE measures the company's profitability relative to shareholders' equity.

Is SLXN's ROE good?

SILEXION THERAPEUTICS CORP (SLXN) has a ROE of -563.11% — below the 10% floor Zyberno applies to healthcare companies where IP and regulatory advantages drive equity returns, indicating weak returns on shareholders' capital. Note: with a debt-to-equity of 9.66x, leverage is amplifying these returns — compare with ROIC (-525.30%) for a leverage-neutral view.

What is the difference between ROE and ROIC?

ROE measures returns on shareholder equity only, while ROIC measures returns on all invested capital (debt + equity). SLXN's ROE is -563.11% vs ROIC of -525.30%. ROE can be inflated by high debt, making ROIC often a more reliable quality metric.

Can high ROE be misleading?

Yes, high ROE can be misleading if achieved through high debt. SLXN's debt-to-equity ratio is 9.66x. Compare ROE to ROIC — if ROE is much higher than ROIC, the company uses significant leverage which adds risk.

📊 Full SLXN Stock Report

See SLXN's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

🏆 SLXN ROIC

Compare to Return on Invested Capital — the most comprehensive measure of capital efficiency.

💹 SLXN P/E Ratio

Analyze the price-to-earnings ratio and earnings yield as a valuation metric.

🎯 SLXN Earnings Surprise (SUE)

See whether SLXN is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

👤 SLXN Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 SLXN Net Income

See the bottom-line profit that drives return calculations.

📊 SLXN EPS

Earnings per share — net income on a per-share basis.

View Full SLXN Report Find More Quality Stocks
Scroll to Top